Hong Kong Government   Report issue

Government Phase 2 Phase 3 Phase 4
Founded: Hong Kong Hong Kong (1950)

Organization Overview

First Clinical Trial
2008
NCT00741936
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Food and Health Bureau, Hong Kong | Hong Kong Council on Smoking and Health

Active Ingredients

Drugs in Phase 4 Trials (2)

abobotulinumtoxinA (Dysport) (1 trial)

empagliflozin (jardiance) (1 trial)

Drugs in Phase 3 Trials (4)

berberine (1 trial)

oseltamivir (tamiflu) (1 trial)

simvastatin (zocor) (1 trial)

zanamivir (relenza) (1 trial)

Drugs in Phase 2 Trials (1)

mazirenwan (1 trial)

Drugs in Other Trials (1)

nicotine (nicorette) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blepharospasm (Phase 4)

Communicable Diseases (Phase 3)

Constipation (Phase 2)

Digestive System Diseases (Phase 2)

Fatty Liver (Phase 4)

Gastrointestinal Diseases (Phase 2)

Hemifacial Spasm (Phase 4)

Hemorrhage (Phase 3)

Infections (Phase 3)

Influenza, Human (Phase 3)

Liver Diseases (Phase 4)

Non-alcoholic Fatty Liver Disease (Phase 4)

Orthomyxoviridae Infections (Phase 3)

Respiratory Tract Infections (Phase 3)

Spasm (Phase 4)

Subarachnoid Hemorrhage (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 8